- Investing.com
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Metrics to compare | IMNM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMNMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −12.3x | −4.2x | −0.5x | |
PEG Ratio | −0.24 | −0.14 | 0.00 | |
Price/Book | 10.4x | 2.0x | 2.6x | |
Price / LTM Sales | 283.0x | 169.1x | 3.3x | |
Upside (Analyst Target) | 38.9% | 143.1% | 48.1% | |
Fair Value Upside | Unlock | −7.7% | 7.7% | Unlock |